Lipid synthesis switch
SREBP-1c↓
Also searched as SREBP-1c.
Named in seven mechanism lists across steatosis, lipids, insulin and liver. PPAR-alpha opposes it; the balance sets hepatic fat.
In depth
Sterol regulatory element-binding protein - the transcription factor driving de novo lipogenesis.
What drives it
Growth restraint increases it.
PMC2593919 — Drawn from the reviews of this outcome. Verbatim: “Activation of mTORC1 signaling induces SREBP activation in cell culture models and in the liver, leading to the accumulation of mature processed SREBP”. doi 10.1038/onc.2015.179 · PMID 26028026 · PMC2593919
Energy sensing reduces it.
10.3389/fphar.2018.00345 — 21459323 — Drawn from the reviews of this outcome. doi 10.3389/fphar.2018.00345
Insulin sensitivity reduces it.
PMC4961151 — Drawn from the reviews of this outcome. PMC4961151
Fatty-acid oxidation increases it.
10.1038/s41598-017-10523-7 — Drawn from the reviews of this outcome. doi 10.1038/s41598-017-10523-7
What it drives
It reduces Kidney.
10.3389/fphar.2020.00265 — 16046411 — Drawn from the reviews of this outcome. doi 10.3389/fphar.2020.00265
It increases PCOS.
SREBP-1c drives de novo lipogenesis; its activation accompanies the insulin-resistant, lipogenic state of PCOS. PMC7005133
It increases Clears liver fat.
10.1038/s41419-020-2472-6 — Drawn from the reviews of this outcome. Verbatim: “SREBP-1c knockdown in CONVR ZFD-fed mice reduced hepatic steatosis and suppressed fatty acid synthase expression”. doi 10.1038/s41419-020-2472-6 · PMID 40345386 · PMC12145984
It reduces Insulin sensitivity.
10.1038/s41401-021-00740-2 — Drawn from the reviews of this outcome. Verbatim: “In insulin signaling, it has been demonstrated that SREBP-1c binding to the Irs-1 promoter region suppresses Irs-1 gene transcription that leads to insulin resistance in the skeletal muscle”. doi 10.1038/s41401-021-00740-2 · PMID 30271747 · PMC6160306
It increases Fasting insulin.
Drawn from the reviews of this outcome.
It increases Type 2 diabetes.
SREBP-1c activation is downstream of hyperinsulinemia and drives hepatic lipogenesis, worsening glycemic control. PMC7005133
It reduces Lowers cholesterol.
10.1172/JCI15593 — Drawn from the reviews of this outcome. doi 10.1172/JCI15593
It reduces Liver.
10.1172/JCI15593 — The aging outcome lists the thirteen hallmarks themselves, each mapped to its pathway and labeled with its hallmark number. (from the reviews of this outcome). Verbatim: “In the liver, SREBPs are involved in the pathogenesis of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, hepatitis and hepatic cancer”. doi 10.1172/JCI15593 · PMID 30271747 · PMC6160306
It increases Liver fat gene.
PNPLA3 is a direct SREBP-1c target gene, strongly induced by feeding and insulin. doi 10.1186/s41021-022-00246-1
It increases Fat-cell formation↓.
ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. doi 10.1101/gad.10.9.1096
Blends that modulate it
Each blend page names this pathway and carries the study behind its claim.
See it on the map
Open the causal map to follow this pathway upstream and downstream, arrow by arrow, each with its study.